Visualisation of the biological effects of small molecules on tuberculosis bacteria.

Eachan Johnson : Publications


  1. Johnson EO, Office E, Kawate T, Orzechowski M, Hung DT. Large-scale chemical-genetic strategy enables the design of antimicrobial combination chemotherapy in Mycobacteria. ACS Infectious Diseases, Jan 2020, 6(1), 56–63.
  2. Johnson EO, Hung DT. A point of inflection and reflection on systems chemical biology. ACS Chemical Biology, Dec 2019, 14(12), 2497–2511. (Review)
  3. Johnson EO, LaVerriere E, Office E, Stanley M, Meyer E, Kawate T, Gomez J, Audette RE, Bandyopadhyay N, Betancourt N, Delano K, Da Silva I, Davis J, Gallo C, Gardner M, Golas A, Guinn KM, Kennedy S, Korn R, McConnell JA, Moss CE, Murphy KC, Nietupski R, Papavinasasundaram KG, Pinkham JT, Pino PA, Proulx MK, Ruecker N, Song N, Thompson M, Trujillo C, Wakabayashi S, Wallach JB, Watson C, Ioerger TR, Lander ES, Hubbard BK, Serrano-Wu MH, Ehrt S, Fitzgerald M, Rubin EJ, Sassetti CM, Schnappinger D, Hung DT. Large-scale chemical-genetics yields new M. tuberculosis inhibitor classes. Nature, Jun 2019, 571, 72–78.
  4. Bowen AM, Johnson EO, Mercuri F, Hoskins NJ, Qiao R, McCullagh JSO, Lovett JE, Bell SG, Zhou W, Timmel CR, Wong LL, Harmer JR. A structural model of a P450-ferredoxin complex from orientation-selective double electron-electron resonance spectroscopy. Journal of the American Chemical Society, Feb 2018, 140(7), 2514–2527.
  5. Johnson EO, Wong LL. Partial fusion of a cytochrome P450 system by carboxy-terminal attachment of putidaredoxin reductase to P450cam (CYP101A1). Catalysis Science and Technology, Sep 2016, 6(20), 7549–7560.
  6. Bell SG, McMillan JH, Yorke JA, Kavanagh E, Johnson EO, Wong LL. Tailoring an alien ferredoxin to support native-like P450 monooxygenase activity. Chemical Communications, Dec 2012, 48(95), 11692–11694.
  7. Boehringer J, Riedinger C, Paraskevopoulos K, Johnson EO, Lowe ED, Khoudian C, Smith D, Noble ME, Gordon C, Endicott JA. Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation. Biochemical Journal, Nov 2012, 448(1), 55–65.
  8. Bell SG, Yang W, Tan AB, Zhou R, Johnson EO, Zhang A, Zhou W, Rao Z, Wong LL. The crystal structures of 4-methoxybenzoate bound CYP199A2 and CYP199A4: structural changes on substrate binding and the identification of an anion binding site. Dalton Transactions, Jul 2012, 41(28), 8703–8714.
  9. Bell SG, Tan AB, Johnson EO, Wong LL. Selective oxidative demethylation of veratric acid to vanillic acid by CYP199A4 from Rhodopseudomonas palustris HaA2. Molecular BioSystems, Jan 2010, 6(1), 206–214.
  10. Bell SG, Xu F, Johnson EO, Forward IM, Bartlam M, Rao Z, Wong LL. Protein recognition in ferredoxin-P450 electron transfer in the class I CYP199A2 system from Rhodopseudomonas palustris. Journal of Biological Inorganic Chemistry, Mar 2010, 15(3), 315–28.
  11. Xu F, Bell SG, Peng Y, Johnson EO, Bartlam M, Rao Z, Wong LL. Crystal structure of a ferredoxin reductase for the CYP199A2 system from Rhodopseudomonas palustris. Proteins, Dec 2009, 77(4), 867–880.